Intravitreal adalimumab for refractory uveitis-related macular edema
Loading...
Date
Authors
Androudi, S.
Tsironi, E.
Kalogeropoulos, C.
Theodoridou, A.
Brazitikos, P.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Type
Type of the conference item
Journal type
peer-reviewed
Educational material type
Conference Name
Journal name
Ophthalmology
Book name
Book series
Book edition
Alternative title / Subtitle
Description
OBJECTIVE: To evaluate the safety and efficacy of intravitreal adalimumab injections on refractory cystoid macular edema (CME) secondary to noninfectious uveitis. DESIGN: Prospective, noncomparative, interventional case series. PARTICIPANTS: Eight consecutive patients with controlled uveitis and chronic, refractory CME who had failed steroid treatment. INTERVENTION: Intravitreal adalimumab injections were given monthly for 3 months. MAIN OUTCOME MEASURES: Mean change in central retinal thickness (CRT) on optical coherence tomography (OCT); secondary objective was the mean change in best-corrected visual acuity (BCVA). RESULTS: Five of the eight patients completed the 6-month follow-up. For all 5 patients, the changes in BCVA from baseline to 3 months were not statistically significant (P=0.070). Similarly, the change in BCVA from baseline to 6 months was not statistically significant (P=1.0). The mean CRT at baseline was 692 microm. The changes from baseline to 3 months were not statistically significant (P=0.466); the changes from baseline to 6 months were also not statistically significant (P=0.808). We did not observe any ocular or systemic adverse effects. CONCLUSIONS: Intravitreal adalimumab showed no efficacy in improving BCVA or reducing CRT in patients with chronic uveitic macular edema.
Description
Keywords
Adult, Anti-Inflammatory Agents/*administration & dosage, Antibodies, Monoclonal/*administration & dosage, Antibodies, Monoclonal, Humanized, Female, Follow-Up Studies, Humans, Injections, Macular Edema/*drug therapy/etiology, Male, Middle Aged, Prospective Studies, Retina/drug effects, Retreatment, Tomography, Optical Coherence, Tumor Necrosis Factor-alpha/antagonists & inhibitors, Uveitis/complications/*drug therapy, Visual Acuity/drug effects, Vitreous Body, Young Adult
Subject classification
Citation
Link
http://www.ncbi.nlm.nih.gov/pubmed/20378179
http://ac.els-cdn.com/S0161642009014158/1-s2.0-S0161642009014158-main.pdf?_tid=ac28974acc4b36c6599a472e2cfefe68&acdnat=1332775403_a2264a93a717dd0775208cd825abcfa7
http://ac.els-cdn.com/S0161642009014158/1-s2.0-S0161642009014158-main.pdf?_tid=ac28974acc4b36c6599a472e2cfefe68&acdnat=1332775403_a2264a93a717dd0775208cd825abcfa7
Language
en
Publishing department/division
Advisor name
Examining committee
General Description / Additional Comments
Institution and School/Department of submitter
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής